Table 2.
Overview of indications for WCD therapy in clinical studies.
| Study | Study design | N of pts⁎ |
Primary vs. secondary prevention |
Duration of use, in days⁎⁎ | Daily use, in hours | ICD Explantation | ICM | NICM | NICM Subgroups |
WL for heart transplantation | During diagnostic wrap up (e.g., channelopathies) |
Acute infection |
Bridge to ablation |
Delayed ICD Implantation | Other/ data not available | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Idiopathic/ DCM | PPCM | Myocarditis | TCM | Others | |||||||||||||||
| VEST [10,22] | RCT | 1524 | 100% vs. 0% | 84.3 | 14,10 | 0 | 1524 (100%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Röger, 2018 [33] | OS | 105 | NR | 68.8 ± 50.4 | 21.5 ± 3.5 | 15 (14%) | 43 (41%) | 41 (39%) | 38 | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 6 (6%) |
| Erath, 2018 [25] | OS | 130 | NR | 42 (1–166) | 23,00 | 0 | 84 (65%) | 46 (35%) | 25 | NR | 5 | 10 | 5 | 0 | 0 | 0 | 0 | 0 | 0 |
| Erath, 2017 [26] | OS | 102 | NR | 42 | 20,00 | 0 | 27 (27%) | 42 (41%) | 33 | 0 | 9 | 0 | 0 | 0 | 4 (4%) | 25 (25%) | 0 | 0 | 4 (4%) |
| WEARIT-II [24,[28], [29], [30], [31]] | OS | 2000 | NR | 90 | 22,5 | 0 | 805 (40%) | 927 (46%) | NR | NR | NR | NR | NR | 0 | 0 | 0 | 0 | 0 | 268 (13%) |
| WEARIT-FR [27] | OS | 1164 | NR | 62 (37–97) | 23.4 | 119 (10%) | 950 (82%) | 0 | 0 | 0 | 0 | 0 | 0 | 88 (8%) | 0 | 0 | 0 | 0 | 7 (1%) |
| WEARIT-II-EU [36] | OS | 781 | NR | 75 ± 47.7 | 20.3⁎ | 0 | 200 (26%) | 249 (32%) | NR | NR | NR | NR | NR | 0 | 102 (13%) | 0 | 0 | 0 | 230 (29%)a |
| Odeneg, 2019 [32] | OS | 448 | 52% vs. 48% | 54 (1, 436) | 23.5 | 46 (10%) | 88 (20%) | 139 (31%)b | NR | NR | 45 | NR | NR | 0 | 0 | 18 (4%) | 11 (2%) | 54 (12%) | 92 (21% |
| Rosenkaimer, 2020 [34] | OS | 153 | NR | 65.1 ± 42 | 21.45 ± 3.52 | 16 (10%) | 56 (37%) | 78 (51%) | NR | NR | 8 | NR | NR | 0 | 0 | 0 | 0 | 0 | 3 (2%) |
| Sinha, 2021 [35] | OS | 120 | NR | 48 (37–62) | 22.9 (21.2–23.4) | 0 | 46 (38%) | 69 (58%) | NR | NR | NR | NR | NR | 0 | 0 | 0 | 0 | 0 | 5 (4%) |
| Weiss, 2019 [37] | cOS | 85 | NR | 59 (40–96) | 20 ± 5 | 8 (9%) | 20 (24%) | 57 (67%) | NR | NR | NR | NR | NR | 0 | 0 | 0 | 0 | 0 | 0 |
| Burch 2021 [23] | OS | 210 | NR | NR | NR | 0 | 91 (43.3%) | 113 (53.8%) | NR | NR | NR | NR | NR | 0 | 0 | 0 | 0 | 0 | 6 (2.9%) |
Structure of table informed by [9].
Abbreviations: cOS – comparative observational study; DCM – dilated cardiomyopathy; ICD – implantable cardioverter defibrillator; ICM – ischemic cardiomyopathy; NICM – non-ischemic cardiomyopathy; NR – not reported; OS – observational study; PCM – peripartum cardiomyopathy; pts – patients; TCM – tachymyopathy; WL – waiting list.
⁎
N of patients refers to patents receiving a WCD.
⁎⁎
All values as median (IQR: 1st Quartile-3rd Quartile or range: lowest value, highest value) or Mean ± SD.
a
Recent onset/ impairment of heart failure.
b
Severe NICM with LVEF<35%.